Carcinoma en Cuirasse is an Independent Poor Survival Predictor in Breast Carcinoma Patients with Cutaneous Metastasis
Description
This supplemental file accompanies our manuscript on the clinical characteristics and prognostic factors of breast cancer patients presenting with cutaneous metastasis. It contains detailed additional figures and tables to support and expand upon the analyses presented in the main article. Supplemental Figure 1: Kaplan-Meier curves depicting significant differences in overall survival (OS) among breast cancer patients stratified by metastatic involvement. Patients are categorized into three groups: (1) cutaneous metastasis only (best prognosis), (2) cutaneous plus lymph node metastasis (intermediate prognosis), and (3) cutaneous plus distant metastasis (worst prognosis). Differences between groups were statistically significant. Supplemental Figure 2: Multivariable stepwise selection analyses evaluating clinicopathological features affecting overall survival (OS) and cutaneous metastasis-free survival (CMFS). Both forward and backward stepwise regression methods were employed to construct a robust final predictive model (global model significance: p-value < 0.0001, log-rank test). Supplemental Figure 3: Results from the multivariable stepwise selection analysis specifically modeling clinicopathological predictors of cutaneous metastasis-free survival (CMFS) in breast cancer patients presenting with skin metastasis. Supplemental Table 1: Clinicopathological details of 11 breast cancer patients specifically presenting with carcinoma en cuirasse. Data include patient demographics (age), clinical descriptions of skin lesions, duration of lesion presence, histological confirmation of breast carcinoma, and receptor status of cutaneous metastasis (Luminal A, Luminal B HER2-negative, Triple Negative, or unavailable). Supplemental Table 2: Multivariable Cox regression analysis identifying key prognostic factors significantly associated with cutaneous metastasis-specific survival (CMSS). The table details hazard ratios, 95% confidence intervals, and corresponding p-values.